Compare Vanguard S&P 500 ETF (VOO) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance

Vanguard S&P 500 ETFTrade

State Street SPDR S&P Biotech ETFTrade

Price performance (Past 24H)

Key statistics

Vanguard S&P 500 ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Vanguard S&P 500 ETF trades at $702.1, while State Street SPDR S&P Biotech ETF trades at $159.93. Which is the better fit depends on your goals.

	VOO	XBI
Sector	Broad Market / Factor	Broad Market / Factor
52-Week High	$714.90	$169.55
52-Week Low	$580.93	$93.43

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Vanguard S&P 500 ETF

VOO trades at $704.09, down 0.56% on the day, with a neutral technical signal and bullish moving averages. Support is firm near $701, while resistance sits at $707. The ETF remains a core S&P 500 holding, with recent news highlighting its tax efficiency versus gold ETFs and strong inflows amid record ETF launches in 2026.

Long-term outlook remains positive given historical S&P 500 performance, though risks include elevated market valuations and Fed policy uncertainty. The ETF offers broad market exposure, but investors face potential volatility from macroeconomic factors and high concentration in top AI-driven companies.

State Street SPDR S&P Biotech ETF

XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.

Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

VOO

Gold ETF gains taxed at 28%, nearly double S&P 500 ETF's 15% rate, costing investors thousands more.24/7 Wall Street · 13 hours agoBearish Four ETFs combine dividend income and total return to balance retirement income and growth risks.24/7 Wall Street · 1 day agoBullish S&P 500 moves with Fed rate hike odds; key 7620 level could signal buying opportunity after September CPI.Seeking Alpha · 2 days agoNeutral View details →

XBI

Biotech ETF IBB outperformed S&P 500 by 22 points in 3 months amid pharma patent cliff deals.24/7 Wall Street · 2 days agoBullish State Street SPDR S&P Biotech ETF (XBI) rated Buy with 8%-14% returns expected despite prior 76% rallySeeking Alpha · 4 days agoBullish View details →

About Vanguard S&P 500 ETF

VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.

About State Street SPDR S&P Biotech ETF

XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.